Reuters logo
BRIEF-GlaxoSmithkline receives European marketing authorisation for self-injectable formulation of Benlysta for treatment of systemic lupus erythematosus
November 13, 2017 / 10:19 AM / 10 days ago

BRIEF-GlaxoSmithkline receives European marketing authorisation for self-injectable formulation of Benlysta for treatment of systemic lupus erythematosus

Nov 13 (Reuters) - GLAXOSMITHKLINE PLC:

* RECEIVES EUROPEAN MARKETING AUTHORISATION FOR SELF-INJECTABLE FORMULATION OF BENLYSTA FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS​

* ‍APPROVAL IS FOR A SINGLE-DOSE PREFILLED SYRINGE AND A SINGLE-DOSE PREFILLED PEN , ADMINISTERED AS A ONCE WEEKLY INJECTION OF 200MG​ Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below